Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo NV's gross profit for the
six
months ended in Jun. 2026 was CHF20.56 Mil. Cosmo NV's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was CHF43.34 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Cosmo NV's gross profit for the
six
months ended in Jun. 2026 was CHF20.56 Mil. Cosmo NV's Revenue for the
six
months ended in Jun. 2026 was CHF46.26 Mil. Therefore, Cosmo NV's Gross Margin % for the quarter that ended in Jun. 2026 was 44.45%.
Cosmo NV had a gross margin of 44.45% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Cosmo NV was 89.11%. The lowest was 45.52%. And the median was 82.25%.
Warning Sign:
Cosmo NV gross margin has been in long-term decline. The average rate of decline per year is -6.8%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cosmo NV had a gross margin of 44.45% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Cosmo NV Gross Profit Related Terms
Cosmo NV Gross Profit Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:COPN vs LLY, JNJ, ABBV: Gross Profit Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Gross Profit distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF43.34 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cosmo NV (XSWX:COPN) has a Gross Profit of CHF43.34 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Cosmo NV and its competitors.
Is Cosmo NV's Gross Profit too high?
Cosmo NV's current Gross Profit is CHF43.34 Mil. Overall, Cosmo NV has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Gross Profit compare to LLY and JNJ?
Cosmo NV's Gross Profit of CHF43.34 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Cosmo NV and its competitors. Cosmo NV's current Gross Profit is CHF43.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (XSWX:COPN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF40.66, compared to a current price of CHF60.60 — trading 49% above its estimated fair value. The current Gross Profit is CHF43.34 Mil. Cosmo NV's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Cosmo NV (XSWX:COPN), the current Gross Profit is CHF43.34 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (XSWX:COPN) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of CHF60.60 is trading 49% above its estimated GF Value™ of CHF40.66.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for XSWX:COPN:
Gross Profit: CHF43.34 Mil
GF Value™: CHF40.66 vs. price of CHF60.60 (49% above fair value)
No single metric tells the full story. See the XSWX:COPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
79GF Score
Get the complete analysis for XSWX:COPN
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:COPN has been successfully added to your 
